Grail Stock Climbs 12.4% on Analyst Bet for Galleri Test Approval

Edgen Stock·Mar 21 2026, 10:36

Share to

Share to

Copy link

Key Takeaways

Grail's stock (NASDAQ: GRAL) gained significantly as investors followed a key analyst upgrade, betting that positive secondary data from its Galleri cancer test trial will outweigh a missed primary endpoint and secure eventual FDA approval. The move highlights a high-stakes valuation debate for the diagnostics company.

Grail shares rose 12.4% over one week after a TD Cowen analyst upgraded the stock to "buy," despite cutting the price target to $65.
Investor optimism persists even after Grail's Galleri test missed its primary endpoint in a landmark UK trial, focusing instead on a demonstrated increase in early-stage cancer detection.
The bet on future approval contrasts with the firm's financial reality, which includes a net loss of $408 million on $147 million in annual revenue.

GRAL Gains 12.4% as Analyst Bets on Galleri's Future

Shares of cancer-detection firm Grail (NASDAQ: GRAL) climbed as much as 12.4% during the week of March 21, 2026, driven by a pivotal analyst upgrade. TD Cowen revised its rating on the stock from "hold" to "buy," signaling renewed confidence in the company's prospects. The endorsement was tempered by a price target cut from $110 to $65 per share. However, this revised target still represented a significant 39% premium over the stock's closing price, fueling investor buying that pushed shares from a recent price of approximately $43.06.

Investors Look Past Missed Endpoint in UK Trial

The bullish sentiment from Wall Street comes even after Grail announced that its Galleri test failed to meet its primary endpoint in a major UK trial. The study did not achieve a statistically significant reduction in combined Stage III-IV cancer diagnoses. Despite this setback, investors are focusing on more promising secondary results. The trial data revealed a "substantial increase" in the detection of Stage I-II cancers and a "clinically meaningful reduction in Stage IV diagnoses" across a group of 12 particularly deadly cancers. Analysts now speculate that follow-up data from the trial could still provide a strong enough case to secure Food and Drug Administration (FDA) approval and insurance coverage.

FDA Approval Remains High-Stakes Bet Amid $408M Loss

The path to regulatory approval is critical for Grail, which currently operates at a significant financial deficit, posting a net loss of $408.4 million against annual revenues of $147.2 million. The high stakes were underscored on March 17, 2026, when competitor Myriad Genetics received FDA approval for its MyChoice CDx ovarian cancer test, demonstrating the immense value unlocked by regulatory green lights in the diagnostics sector. While some narratives project a potential fair value for Grail as high as $88 per share based on future growth, this optimistic valuation hinges entirely on the Galleri test successfully navigating the FDA—a high-risk, high-reward scenario for shareholders.